BSE filing, NSE: BIOCON. Summary written from the filing by ALFA Finder's alert engine.
Biocon Ltd: key numbers
- Share price
- ₹345.10
- Market cap
- ₹56,241 Cr
- Revenue (annual)
- ₹16,927 Cr
- Net profit (annual)
- ₹385.6 Cr
- P/E (TTM)
- 113.5×Sector 41.3×
- Promoter holding
- 44.68%+0.00% QoQ
- FII holding
- 8.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Biocon Ltd
All →Biocon Q2 FY27 Results: Net Profit ₹56.7 Cr, Down 57.3% YoY
Biocon Ltd reported revenue from operations of ₹4,389 Cr (+2.2% YoY) and net profit of ₹56.7 Cr (-57.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹56.7 Cr · -57.3% YoY
Biocon Board Meeting Date
Biocon schedules a November 4, 2026 board meeting for Q2 FY27 unaudited results, plus an earnings call. Trading window stays closed until November 6, 2026.
Biocon Business Update
Biocon signed a licence agreement with Janssen to commercialise biosimilar Yesintek in nine more markets, including Australia, Brazil and China. No deal value is disclosed.
Biocon Other Announcement
Biocon Ltd has submitted its quarterly shareholding pattern for the period ended September 30, 2026. The filing details the distribution of equity shares among various stakeholder categories.
Biocon Partnership
Biocon entered a global patent settlement and license agreement with Genentech, securing early launch dates for its biosimilar Pebrilzo® (bPertuzumab) across key global markets.
- From
- Genentech
Biocon Legal & Regulatory
Biocon received a GST demand order for ₹3.21 Crore, including tax, interest, and penalty. The company intends to file a rectification application or appeal.
- Value
- ₹3.21 Cr
Other results update announcements
All →Steel Exchange India Results Update
Steel Exchange India Ltd reported a nine-fold surge in Q2 FY27 PAT to ₹18 Crore. Revenue rose 46% to ₹343 Crore alongside a ₹102 Crore debt reduction.
- quarterly production
- 69617.42 MT
Alembic Pharmaceuticals Results Update
Alembic Pharmaceuticals reported Q2 FY27 revenue growth of 36% to ₹2,603 Crore. Net profit surged 81% to ₹335 Crore, driven by exceptional US business performance.
- Value
- ₹2,603 Cr
SJS Enterprises Results Update
S.J.S. Enterprises reported record quarterly revenue of Rs. 282.73 Crore, up 16.9% YoY. Net profit for Q2FY27 rose 34.8% YoY to Rs. 58.33 Crore.
- Value
- ₹282.7 Cr
Meghmani Organics Results Update
MOL reported Q2 FY27 revenue of ₹658.2 crore, up 18% YoY, with net profit of ₹45.3 crore. EBITDA margin eased to 10.8% on elevated input costs.
GPT Infraprojects Results Update
GPT Infraprojects reported Q2 FY27 revenue of ₹291.4 crore and PAT of ₹18.3 crore. Order inflow was ₹1,491 crore; interim dividend of ₹1 declared.
- Order book
- ₹5,373 Cr
Indo Count Industries Results Update
Indo Count reported record Q2 FY27 income of ₹1,699 Cr and PAT of ₹132 Cr. H1 EBITDA grew 73% YoY to ₹420 Cr.